DYN
Dyne Therapeutics Announces Proposed Public Offering of Common Stock
Article Summary
HOLD- Dyne Therapeutics Inc. (Nasdaq: DYN) announced that it has commenced an underwritten public offering of $300,000,000 of shares of its common stock and intends to grant the underwriters a 30-day option to purchase up to an additional $45 million.
- The clinical-stage company is focused on delivering functional improvement for people living with genetically driven neuromuscular diseases.
- All of the shares in the proposed offering are to be sold by Dyne, with Morgan Stanley, Jefferies, Evercore ISI, LifeSci Capital and Raymond James acting as joint book-running managers.
- The proposed offering is subject to market and other conditions and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
- The offering is being made pursuant to a shelf registration statement on Form S-3 previously filed with the Securities and Exchange Commission on March 5, 2024 and became automatically effective upon filing.
Free users see 3 BUY signals per day. Premium unlocks all of them, plus instant email alerts.
See Plans
Growth Stock Scoring Breakdown
| METRIC | VALUE | WEIGHT | ANALYSIS |
|---|---|---|---|
| Sales Growth TTM ? | 0.0% | 25% | 20.0 ptsMinimal (0.0%) - Very weak |
| EPS Growth Next 5Y ? | 15.4% | 25% | 50.0 ptsMeets Minimum (15.4%) - Passes screener |
| Target Price Upside ? | 65.0% | 20% | 100.0 ptsMassive Upside (65.0%) - Target: $39.33 vs Current: $23.83 |
| Gross Margin % ? | — | 15% | 40.0 ptsNo Gross Margin Data |
| Drawdown from 52-Wk High ? | -4.7% | 15% | 20.0 ptsBarely a Dip (-4.7%) - Near recent highs |
Disclaimer: This rating is for informational purposes only and is not financial advice.
All data sourced from Finviz.
Always conduct your own research and consult with a financial advisor before making investment decisions.
Past performance does not guarantee future results.
About DYN
- Dyne Therapeutics, Inc., a clinical-stage neuromuscular disease company, focuses on discovering and developing therapeutics for neuromuscular diseases in the United States.
- The company is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; facioscapulohumeral dystrophy; and Pompe disease, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.
- Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.